PhaseBio Launches Roadshow for Initial Public Offering
October 08, 2018 07:00 ET
|
PhaseBio Pharmaceuticals, Inc.
MALVERN, Pa. and SAN DIEGO, Oct. 08, 2018 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc. (“PhaseBio”), a clinical-stage biopharmaceutical company focused on the development and commercialization...
PhaseBio Announces Positive Results From Phase 1 Clinical Trial of PB2452, a Novel Reversal Agent for Ticagrelor
September 24, 2018 08:00 ET
|
PhaseBio Pharmaceuticals, Inc.
MALVERN, Pa. and SAN DIEGO, Calif., Sept. 24, 2018 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the development and commercialization of...
PhaseBio Secures $34 Million in Series D Financing
September 05, 2018 08:00 ET
|
PhaseBio Pharmaceuticals, Inc.
MALVERN, Pa., Sept. 05, 2018 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for...
PhaseBio Appoints Caroline M. Loewy to Board of Directors
July 19, 2018 08:00 ET
|
PhaseBio Pharmaceuticals, Inc.
MALVERN, Pa., July 19, 2018 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the development of therapies for orphan diseases with an initial...
PhaseBio Names Michael B. York as Vice President of Corporate Development and Commercial Strategy
June 26, 2018 08:00 ET
|
PhaseBio Pharmaceuticals, Inc.
MALVERN, Pa., June 26, 2018 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the development of therapies for orphan diseases with an initial...
PhaseBio Announces Completion of Dosing in First Cohort of Phase 1 Clinical Trial of PB2452, a Reversal Agent for Ticagrelor
April 05, 2018 08:00 ET
|
PhaseBio Pharmaceuticals, Inc.
MALVERN, Pa., April 05, 2018 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing therapies for the treatment of orphan diseases, today announced...
PhaseBio to Present at March Investor Conferences
March 06, 2018 08:00 ET
|
PhaseBio Pharmaceuticals, Inc.
MALVERN, Pa., March 06, 2018 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing therapies for the treatment of orphan diseases, today announced...
PhaseBio Announces Appointments to Board of Directors
March 05, 2018 08:00 ET
|
PhaseBio Pharmaceuticals, Inc.
MALVERN, Pa., March 05, 2018 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing therapies for the treatment of orphan diseases, today announced...
PhaseBio Awarded $2.8 Million NIH SBIR Grant to Support Clinical Development of PB1046 in Pulmonary Arterial Hypertension
February 27, 2018 08:00 ET
|
PhaseBio Pharmaceuticals, Inc.
MALVERN, Pa., Feb. 27, 2018 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing therapies for the treatment of orphan diseases, today announced...
PhaseBio Announces $15.6 Million in Funds to Support Clinical Advancement of Orphan Cardiovascular Pipeline
November 29, 2017 08:00 ET
|
PhaseBio Pharmaceuticals, Inc.
Entered into $7.5 million term loan facility with Silicon Valley BankClosed $8.1 million second tranche of convertible notes announced in January 2017Funds will be used to advance clinical development...